POSTERS ASCO 2024

• Oncología pediátrica

Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma.

Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma.

Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.

Abstract: 10032 Poster Bd #: 399